Table 2 Demographic characteristics and AKI onset time of patients by age category
Variable | Age 18–35 (n = 12,873) | Age 36–55 (n = 25,197) | Age 56–65 (n = 18,098) | Age > 65 (n = 20,789) | ||||
|---|---|---|---|---|---|---|---|---|
AKI | Non-AKI | AKI | Non-AKI | AKI | Non-AKI | AKI | Non-AKI | |
Age, years, n (%) | ||||||||
n (%) | 983 (7.29) | 11,890 (92.71) | 2222 (8.82) | 22,975 (91.18) | 1906 (10.53) | 16,192 (89.47) | 2193 (10.55) | 18,596 (98.45) |
Race, n (%) | ||||||||
White | 660 (67.14) | 8038 (67.60) | 1537 (69.17) | 16,652 (72.48) | 1444 (75.76) | 13,024 (80.43) | 1767 (80.57) | 15,463 (83.15) |
Black | 150 (15.26) | 1958 (16.47) | 420 (18.90) | 3808 (16.57) | 264 (13.85) | 1926 (11.89) | 231 (10.53) | 1644 (8.84) |
Asian | 7 (0.71) | 147 (1.24) | 12 (0.54) | 190 (0.83) | 17 (0.89) | 112 (0.69) | 18 (0.82) | 151 (0.81) |
Other | 121 (12.31) | 1792 (15.07) | 253 (11.39) | 2325 (10.12) | 181 (9.50) | 1130 (6.98) | 177 (8.07) | 1338 (7.20) |
Gender, n (%) | ||||||||
Male | 549 (55.85) | 6066 (51.02) | 1302 (58.60) | 12,337 (53.70) | 1170 (61.39) | 9297 (57.42) | 1288 (58.73) | 10,150 (54.58) |
BMI, n (%) | ||||||||
Unknown | 39 (4.16) | 1209 (10.13) | 92 (4.14) | 1848 (8.04) | 57 (2.99) | 830 (5.13) | 65 (2.96) | 947 (5.09) |
< 18.5 | 81 (8.63) | 563 (4.72) | 56 (2.52) | 537 (2.34) | 44 (2.31) | 479 (2.96) | 69 (3.15) | 680 (3.66) |
18.5–24.9 | 325 (34.65) | 4076 (34.15) | 460 (20.70) | 5133 (22.34) | 379 (19.88) | 3630 (22.42) | 535 (24.40) | 5542 (29.80) |
25.0–29.9 | 201 (21.43) | 2594 (21.73) | 567 (25.52) | 5879 (25.59) | 493 (25.87) | 4454 (27.51) | 701 (31.97) | 5950 (32.00) |
> 30.0 | 292 (31.13) | 3493 (29.27) | 1047 (47.12) | 9578 (41.69) | 933 (48.95) | 6799 (41.99) | 823 (37.53) | 5477 (29.45) |
DRG, Liver transplant (LT), Cystic fibrosis (CF), Heart failure (HF), n (%) | ||||||||
LT | 9 (0.96) | 9 (0.08) | 68 (3.06) | 49 (0.21) | 65 (3.41) | 69 (0.43) | 15 (0.68) | 20 (0.11) |
CF | 121 (12.90) | 564 (4.73) | 26 (1.17) | 125 (0.54) | 6 (0.31) | 39(.24) | 0 (0.00) | 3 (0.02) |
HF | 6 (0.64) | 19 (0.16) | 45 (2.03) | 127 (0.55) | 36 (1.89) | 121 (0.75) | 62 (2.83) | 277 (1.49) |
CCS, Nutritional deficiencies (ND), Esophageal disorders (ED), Essential hypertension (EH), n (%) | ||||||||
ND | 193 (20.58) | 1040 (8.71) | 203 (9.14) | 1844 (8.03) | 156 (8.18) | 1416 (8.75) | 172 (7.84) | 1721 (9.25) |
ED | 112 (11.94) | 585 (4.90) | 228 (10.26) | 2283 (9.94) | 239 (12.54) | 1959 (12.10) | 271 (12.36) | 2551 (13.72) |
EH | 104 (11.09) | 886 (7.42) | 648 (29.16) | 5834 (25.39) | 825 (43.28) | 5968 (36.86) | 1053 (48.02) | 8715 (6.86) |
MED, Tazobactam (T), Vancomycin (V), Acetaminophen (A), n (%) | ||||||||
T | 403 (42.96) | 2089 (17.50) | 791 (35.60) | 3742 (16.29) | 567 (29.75) | 2662 (16.44) | 515 (23.48) | 2892 (15.55) |
V | 366 (39.02) | 1936 (16.22) | 762 (34.29) | 4485 (19.52) | 620 (32.53) | 3656 (22.58) | 655 (29.87) | 489 (22.53) |
A | 755 (80.49) | 9883 (82.81) | 1816 (81.73) | 19,782 (86.10) | 1585 (83.16) | 14,097 (87.06) | 1889 (86.14) | 16,601 (89.27) |
Onset time, days, median [interquartile range] | ||||||||
Days | 3 [2–6] | – | 3 [2–5] | – | 3 [2–6] | – | 3 [2–6] | – |